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Edited by Beat ImhofAbstract A novel superfamily of guanine nucleotide exchange
factors for Rho GTPases includes DOCK180 and zizimin1.
The zizimin subfamily includes three genes of which only zizi-
min1 has been cloned. We report here the cloning of zizimin2,
identiﬁed in a screen for genes enriched in germinal center B
cells. Zizimin2 and zizimin1 have similar primary structures
and both proteins bound and activated Cdc42 but not the
Cdc42-related proteins TC10 or TCL. Their tissue distributions
are distinct, however, with zizimin2 expressed predominantly in
lymphocytes and an opposite pattern for zizimin1. Zizimin3
was also analyzed and showed distinct GTPase speciﬁcity and
tissue distribution.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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During versatile adaptive immune responses, germinal cen-
ters (GCs) are formed in peripheral lymphoid tissues. GCs play
central roles in diﬀerentiation of late B cells to antibody-secret-
ing plasma cells or to antigen-speciﬁc memory B cells. The dif-
ferentiation processes include immunoglobulin class-switching,
somatic hypermutation and aﬃnity maturation through B cell
receptor-dependent signals by encountering the cognate anti-
gens [1,2]. During these processes, the activated B lymphocytes
migrate from the central to the marginal zone of the GC. A
number of genes were recently shown by gene expression pro-Abbreviations: GC, germinal center; BCR, B cell receptor; GEF, gu-
anine nucleotide exchange factor; CDM, CED-5, DOCK180, Myo-
blast city; CZH, CDM-zizimin homology; GFP, green ﬂuorescence
protein; PNA, peanuts agglutinin; PH, pleckstrin homology; GST,
glutathione S-transferase; PAK, p21-activated kinase; PBD, p21 bin-
ding domain; PBL, peripheral blood lymphocytes
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tion through GCs [3,4].
The Rho family of low molecular weight GTPases are piv-
otal regulators of the actin cytoskeleton and many other cellu-
lar processes [5–7]. Rho proteins include twenty-two human
genes that can be divided to six or more subfamilies [8]. The
three major subfamilies are the RhoA, Rac1 and Cdc42 pro-
teins. Cdc42 mediates cell polarity, gene expression, cell cycle
progression and cell–cell contacts [9,10]. In lymphocytes,
Cdc42 was shown to be essential for chemokine-induced T cell
migration and to regulate T cell polarization towards antigen-
presenting cells [11].
Like other GTPases, Rho proteins are active when bound to
GTP and inactive when bound to GDP. Conversion of the
GDP-bound proteins to the active state is catalyzed by guanine
nucleotide exchange factors (GEFs). The classical GEFs for
Rho GTPases comprising a family of over sixty proteins [12],
share a common motif, designated the Dbl-homology (DH)
domain that mediates nucleotide exchange [13]. Additionally,
a second family of GEFs that utilize an alternative Rho-
GEF domain was recently discovered. Why two diﬀerent do-
mains evolved is an open question but the inﬂation in Rho
GEFs may reﬂect the need for selective activation of Rho pro-
teins by diﬀerent signaling pathways and under diverse
conditions.
This new family of Rho-GEFs was named CZH because it in-
cludes CDM (Ced-5, DOCK180, Myoblast city) proteins that
activate Rac, and zizimin1 that activates Cdc42 [14–17]. Using
information from genomic, protein and transcript databases,
the family was predicted to include 11 mammalian genes, many
of which have not been cloned [15,16]. Based on sequence
homology, CZH proteins can be divided into one subfamily re-
lated to CDM proteins and a subfamily related to zizimin1. The
two groups share two conserved domains that we named CZH1
and CZH2 for CDM-zizimin homology 1 and 2, respectively
[16]. The CZH2 domain, also called DOCKER or DHR2, is
a GEF domain that shows no sequence homology to DH do-
mains [14–16]. The function of the CZH1 domain, also named
DHR1, remains unknown [15,16]. Based on sequence similar-
ity, domain structure and phylogenetic analysis the zizimin-re-
lated proteins can be divided to two groups. The ﬁrst, named
zizimin proteins or DOCK-D, includes three proteins
zizimin1/DOCK9, zizimin2/DOCK11 and zizimin3/DOCK10,blished by Elsevier B.V. All rights reserved.
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named zir for zizimin-related, or DOCK-C, includes zir1/
DOCK6, zir1/DOCK7 and zir3/DOCK8 of which only
DOCK8 was cloned [15,16,18].
Using subtractive hybridization, in this study we cloned zizi-
min2 as a gene expressed at higher levels in GC B cells com-
pared to non-GC B cells. Zizimin2 primary structure is
similar to zizimin1, exhibiting 60% identity in amino acid se-
quence. We show that zizimin2 and zizimin1 bind selectively
to Cdc42 but not Rac Rho or the Cdc42-related proteins
TC10 and TCL. Overexpression of zizimin2 activates Cdc42
in cells. Zizimin2 is expressed predominantly in lymphocytes
in contrast to zizimin1 which is enriched in non-hematopoietic
tissues. The GTPase speciﬁcity and tissue distribution of zizi-
min3 were also analyzed.2. Materials and methods
2.1. Vectors and bacterial expression
pHis full-length (FL) zizimin2 was generated by inserting the PCR-
ampliﬁed full length zizimin2 cDNA into pcDNA-4-His-max (Invitro-
gen) using the NotI site. To construct a vector for expression of green
ﬂuorescence protein (GFP) fusion proteins with additional tags (pGT),
a fragment coding for myc-ﬂag-HA tags was cloned into XhoI/EcoRI
site of the pEGFP-C1 vector (Clontech). Zizimin2 (669-E), Zizimin2
(1516-E) and Zizimin1 (1512-E) were ampliﬁed by PCR and cloned
into pGT. pEF-oncoVav1 was described elsewhere [19]. HA-tagged
human zizimin1 CZH2 (Zizimin1 1512-E) was described before [16].
For HA-tagged human zizimin2 CZH2 construction, EST Genbank
accession number H15608 was ampliﬁed by PCR using the primers
5 0-ATA GGT ACC ACC AAA AGG AAA ACC TTT TTG A-3 0
(sense) and 5 0-AAA GAA TTC TCA CAC TTC AGC GTA TCT
TGG G-3 0 (antisense), the product was digested with KpnI and EcoRI
and cloned into KpnI/EcoRI site of pEF4-HA-Kpn [16]. For HA-
tagged human zizimin3 CZH2, EST Genbank accession number
BM905401 was ampliﬁed by PCR using the primers 5 0-ATA GGT
ACC AAC AAG CAG AAG TCA ATT GTC CG-3 0 (sense) and 5 0-
AAG GAT CCT CAG ACT TCA GCA CTA GAT GAG-3 0 (anti-
sense). The product was digested with KpnI and BamHI and cloned
into appropriate sites of the modiﬁed pEF4-HA-Kpn vector which
possessed an additional BamHI site just prior to SfuI site. Glutathione
S-transferase (GST)-TC10 in the bacterial expression vector pGEX2T
was expressed and puriﬁed as described [20]. For GST-TCL protein,
human TCL (Genbank Accession No. AJ276567) in pcDNA3.1, ob-
tained from UMR cDNA resource center at the university of Mis-
souri-Rolla (Rolla, MO), was subcloned into pGEX4T1 using
EcoRI/XhoI sites, expressed and puriﬁed as described for TC10 [20].
2.2. Cell culture and gene introduction
BAF0/3 cells were maintained as described previously [21]. A20, EL-
4, WEHI-231 cell lines and mouse primary splenic cells were cultured
in RPMI 1640 with 50 lM 2-mercaptoethanol. Other cell lines includ-
ing COS-1 and COS-7 cells were cultured in DMEM. All culture media
was supplemented with 10% FCS, 50 units/ml penicillin and 50 lg/ml
streptomycin. Transient transfection of COS-1 cells was performed
with Fugene6 reagent (Roche Diagnostics). COS-7 cells were transfec-
ted using the Eﬀectene Reagent (Qiagen). Cells were harvested at 24–
48 h post transfection.
2.3. Generation of subtracted cDNA library
For GC and non-GC B cells preparation, C57bl/6J mice were immu-
nized with 4-hydroxy-3-nitrophenyl acetyl coupled to chicken globulin
(NP-CG) and single splenocyte suspensions were prepared from
spleens 7 days after priming. CD19+ B cells were isolated by auto
MACS (Miltenyi Biotec) by incubation with FITC-conjugated anti-
CD19 antibody and anti-FITC magnetic beads, followed by removal
of the beads by anti-FITC isolation kit. The isolated CD19+ cells were
found to be positive for B220 as well by FACS analysis (Becton Dick-
inson). The cells were then incubated with biotinylated peanut aggluti-nin (PNA; Vector Laboratories), followed by streptavidin magnetic
beads. PNAhigh or PNAlow B cells were obtained by auto MACS sort-
ing. Total RNA preparation, cDNA synthesis and PCR-select cDNA
subtraction were carried out as described previously [22], the PNAhigh
B cells cDNA was used as tester and the PNAlow B cells cDNA was
used as driver.
2.4. Cloning of zizimin2
Sequences obtained from the subtracted library were used for Gen-
bank searches. A 99 bp clone completely matched sequences of the
putative zizimin2/DOCK11 protein. The hypothetical FL cDNA se-
quence of zizimin2 was generated by combining sequences of overlap-
ping Genbank expressed sequence tag (EST) clones. To obtain the
authentic sequence of zizinin2 as expressed in B cells, primers from
the putative beginning and end of zizimin2 open reading frame (5 0-
GAA AGT GCG CAA ATT CAC C-3 0 and 5 0-TCA TAC TTC
CGC GTA TCT TG-3 0) were designed and PCR was performed using
murine splenic B cells cDNA as template. Consequently, a single prod-
uct 6.2 kb long was ampliﬁed. Three independently ampliﬁed clones
were sequenced to be veriﬁed. Finally the untranslated 5 0 region of
Zizimin2 was determined using the GeneRacer rapid ampliﬁcation of
cDNA end (RACE) kit (Invitrogen) with the following gene speciﬁc
primers, 5 0-TGG CAA CAT CC GAA AGT CCC CAG A-3 0 and
5 0-TGG GCC CTC TTT TCA CAT CCT CTG G-3 0. The sequence
of zizimin2 was deposited at the GenBank database with the accession
number AB116935.
2.5. GTPases binding and activation assays
Transfected cells were washed twice in cold PBS and lysed 10 min
on ice in 50 mM Tris, pH 7.5, 500 mM NaCl, 1% Triton X-100, 5
mM EDTA and 1% protein inhibitors mixture (Sigma # P8340).
The EDTA serves to deplete GTPases from nucleotides by chelating
Mg2+ ions that are essential cofactor for nucleotide binding. Lysates
were cleared by 10 min centrifugation at 16 000 · g. A portion of this
total lysate was reserved and the rest incubated for 1 h at 4 C with
25 lg GST fused GTPases bound to glutathione agarose beads (Sig-
ma). The beads were washed 3 times in lysis buﬀer (LB) and either
eluted directly in SDS–PAGE loading buﬀer (Fig. 2B) or eluted ﬁrst
in LB lacking EDTA and containing 5 mM MgCl2 and 100 lM
GTPcS followed by a elution of the beads in SDS–PAGE loading
buﬀer (Fig. 3). For assaying Cdc42 activation, we used the Cdc42
activation assay kit (Cytoskeleton) according to the manufacturers
instructions.
2.6. RNA analysis
For Northern blotting, total RNA from various mouse tissues was
isolated with TriZol (Invitrogen) and then poly-A+ RNA was puriﬁed
with lMACS mRNA isolation kit (Miltenyi Biotec). Poly-A+ RNA
(0.5 lg) was separated by electrophoresis on 1.5% agarose, 6% formal-
dehyde gels and transferred onto Hybond-N+ membrane (Amersham),
which was hybridized with [32P]-labeled PCR ampliﬁed murine zizi-
min2, zizimin1, zizimin3 or b-actin cDNA probes. The following prim-
ers were used for probe ampliﬁcation: zizimin2, 5 0-GAC AAA ATA
TTG TTA TCC-30 (sense) and 5 0-GCT GGC AAT GAT GGA
AGA AT-3 0 (antisense); zizimin1, 5 0-AAG GTC AAC CCG AAG
GAT CT-3 0 (sense) and 5 0-GGC TCC TTC TCT CTC CCA TT-3 0
(antisense); zizimin3, 5 0-TGG CCA AAG TCG AAA AAG TC-3 0
(sense) and 5 0-GGC TCC ATC GTC ATC TGA AT-30 (antisense).
b-actin probe was purchased from Clontech. Probe hybridization
was performed with Perfecthyb (Sigma) as recommended by the
manufacturer.
Quantitative real-time RT-PCR was carried out as described [22].
Each RNA sample was analyzed in parallel for b-actin to control for
diﬀerences in starting RNA amounts. The following gene speciﬁc prim-
ers were used: human b-actin, 5 0-CCA AGG CCA ACC GCG AGA
AG-3 0 (sense) and 5 0-GCC AGA GGC GTA CAG GGA TA-30 (anti-
sense); mouse and human zizimin2, 5 0-TTG CCT TTT ATG GCC
AGT CT-30 (sense) and 5 0-GAG CGA ATT TTG GAT CAA GC-3 0
(antisense); mouse zizimin1, 5 0-CCA AAT TCC CTG CAC ATC
TT-3 0 (sense) and 5 0-GGC TCC TTC TCT CTC CCA TT-3 0 (anti-
sense); mouse b-actin, 5 0-CTA AGG CCA ACC GTG AAA AG-3 0
(sense) and 5 0-ACC AGA GGC ATA CAG GGA CA-3 0 (antisense).
Especially, for GC and non-GC B cell cDNA preparation in Fig.
4A, four-color sorting (B220, CD19, PNA, and GL-7) was performed
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Bioscience Kobe Laboratory and we prepared cDNAs using SMART
PCR cDNA synthesis method (BD Clontech).3. Results
3.1. Cloning of mouse zizimin2 and sequence analysis
To identify genes potentially involved in late B cell diﬀeren-
tiation, we looked for genes that are upregulated in GC B cells
when compared to non-GC B cells. C57bl/6J mice were immu-
nized with NP-CG and single-splenocyte suspensions were pre-
pared. GC B cells (CD19+ B220+ PNAhigh) and non-GC B cells
(CD19+ B220+ PNAlow) were puriﬁed and total RNA was pre-
pared. cDNA was synthesized and a library prepared of GC-B
cells cDNA subtracted by non-GC B cells cDNA. Genbank
searches using a 99 bp sequence derived from the library
matched sequences of the putative zizimin2/DOCK11 protein
(Fig. 1A). Quantitative RT-PCR analysis was then employed
to conﬁrm higher expression of zizimin2 RNA in GC B cells
(2.6-fold; see Fig. 4A). The hypothetical zizimin2 open reading
frame (ORF) was identiﬁed and primers from the potential
beginning and end of the ORF were designed. These were used
to amplify murine splenic B cells cDNA. A 6.2 kb fragment
was obtained and cloned into vector. Finally, the sequence
coding for the 5 0 untranslated region was identiﬁed by 5 0-
RACE.
The complete sequence obtained bears 6346 nucleotides cod-
ing for a protein of 2073 amino acids with a calculated molec-
ular weight of 238 kDa. Murine zizimin2 shows high sequence
similarity to human zizimin1, which was cloned previously
[16]. Zizimin2 possesses an N-terminus pleckstrin homology
(PH) domain (predicted by the Pfam program [23]), CZH1 do-
main and CZH2 domain (Fig. 1A). The predicted human zizi-
min2 (Genbank GI: 40068509) also contains 2073 amino acids
and displays 96% identity and 98% similarity to the murine
protein.
A third zizimin isoform, named zizimin3 or DOCK10, was
identiﬁed in human by searching protein and genomic dat-
abases with zizimin1 and DOCK180 [15,16]. To compare zizi-
min2 to the other two isoforms, we searched protein and EST
databases for the complete sequences of murine zizimin1 and
zizimin3. Interestingly, several areas of alternative splicing
were identiﬁed. Both zizimin1 and zizimin3 have alternative
amino and carboxy termini while three additional sites of alter-
native splicing were identiﬁed in zizimin1 (Fig. 1C). All ﬁve
alternatively spliced forms of murine zizimin1 are conserved
in human. Database searching identiﬁed no splice isoforms
of zizimin2 (murine or human). We assembled the murine zizi-
min1 and zizimin3 isoforms that exhibit the highest similarity
to zizimin2 and aligned the sequences (Fig. 1B). Murine zizi-
min2 and zizimin1 are 60% identical and 75% similar in amino
acid sequence while zizimin3 displays 50% identity and 67%
similarity to zizimin2. Conservation is evident along most of
the sequence but is highest within the CZH2 domain with
71% identity/85% similarity between zizimin2 and zizimin1
and 66% identity/83% similarity between zizimin2 and zizi-
min3. Overall, the zizimin2 and zizimin1 sequences are more
related to each other than to zizimin3. Interestingly, the zizi-
min2 genes from both mouse and human are located on chro-
mosome X. Mouse zizimin1 and zizimin3 are located on
chromosomes 14 and 1, respectively, while human zizimin1and zizimin3 are located on chromosomes 13 and 2, respec-
tively. The genomic organization of murine zizimin2 was deter-
mined by database search. The predicted zizimin2 gene spans
187,774 bp comprising of 53 exons (Fig. 1A).
3.2. Zizimin2 activates Cdc42 via the CZH2 domain
CZH proteins were shown previously to function as direct
activators of Rho proteins [14–16]. The interaction is mediated
via a novel GEF domain named CZH2, DOCKER or DHR2.
For nucleotide exchange, GEFs ﬁrst bind with low aﬃnity to
the GDP-bound GTPase and induce dissociation of GDP from
this complex, which leads to formation of a higher aﬃnity
intermediate. This intermediate is then dissociated by binding
of GTP [24]. GEFs can therefore be distinguished from other
GTPase interacting proteins by their ability to bind preferen-
tially to the nucleotide-depleted (ND) state compared to
GTP- or GDP-bound states [16,25]. We therefore studied po-
tential interaction of zizimin2 with Cdc42, Rac1 or RhoA by
assaying binding to the nucleotide depleted GTPases using
truncated forms of zizimin2 described in Fig. 2A. As shown
in Fig. 2B, a zizimin2 fragment containing the C-terminal
two thirds of the protein (Zizimin2669-E) bound Cdc42 but
not Rac1 or RhoA. The same GTPases speciﬁcity was previ-
ously shown for zizimin1 [16]. A shorter fragment containing
only zizimin2 CZH2 domain (Zizimin21512-E) was suﬃcient
to mediate Cdc42 binding (Fig. 3). The results therefore impli-
cate zizimin2 as a potential Cdc42-GEF.
To examine whether zizimin2 can activate Cdc42 in cells, FL
zizimin2 was overexpressed in COS-1 cells and GTP-loaded ac-
tive Cdc42 was precipitated using the p21 binding domain
(PBD) of p21-activated kinase (PAK). As shown in Fig. 2C
(left panel), zizimin2 expression induced substantial activation
of endogenous Cdc42. Expression of the isolated CZH2 do-
mains of zizimin2 or zizimin1 (as GFP fusions), was suﬃcient
to induce Cdc42 activation, further supporting the function of
this module as a novel GEF domain (Fig. 2C right panel). Sim-
ilar expression of GFP-zizimin2 CZH2, GFP-zizimin1 CZH2
or the control GFP was conﬁrmed by FACS analysis (data
not shown). We note that previous studies in NIH-3T3 or
293T cells failed to detect Cdc42 activation by the short
CZH2 domain [15,16]. The higher expression level in COS-1
cells may account for the discrepancy.
3.3. Analysis of GTPase selectivity
Rho proteins can be grouped into subfamilies based on
structural and functional similarities. Based on the ability to
promote formation of ﬁlopodia, ﬁve mammalian genes are in-
cluded in the Cdc42-related subfamily, namely: Cdc42, TC10,
TCL, Wrch-1 and Wrch-2 [8]. Wrch-1 and Wrch-2, however,
are structurally and phylogenetically quite distinct from the
other three members [8]. To further deﬁne the selectivity of
zizimin isoforms for diﬀerent GTPases, we compared binding
zizimin1, 2 and 3 to Cdc42, TC10 and TCL. To this end, we
cloned the CZH2 domain of zizimin3 as the FL protein has
not been cloned yet. Lysates of COS-7 cells expressing the
CZH2 domains of zizimin1, 2 or 3 were incubated with nucle-
otide-depleted GTPases bound to agarose beads, which were
washed and eluted with GTP. The GTP elution served to
ascertain the speciﬁcity of the GEFs interaction with the nucle-
otide-depleted GTPases, which should be reversed by GTP
[24]. As shown in Fig. 3 (left panel), both zizimin2 and zizi-
min1 bound Cdc42 but not TC10 or TCL. Zizimin2 CZH2
Fig. 1. Primary structure of zizimin2 and its isoforms. (A) Schematic representation of murine zizimin2 protein and gene structures. Top diagram:
protein structure, the location and boundaries of the PH domain, CDM-zizimin homology 1 (CZH1) domain and the CDM-zizimin homology 2
(CZH2) domain are displayed. The amino acid sequence derived from the cDNA fragment cloned by subtractive hybridization is shown above the
CZH2 domain. Bottom diagram: gene structure, each exon is represented by a vertical bar, exons encoding the PH, CZH1 and CZH2 domains are
indicated. Intron 1 is approximately 55 kb long. (B) Comparison of murine zizimin2, zizimin1 and zizimin3 amino acid sequences. The sequences
were aligned using the Multalin program [31]. Residues in black shading are identical in all proteins and in bold are similar in 2 of the 3 proteins. The
PH, CZH1 and CZH2 domains are boxed. The zizimin1 sequence was assembled from Genbank GI numbers 32469704, 51768647 and 314197757.
The zizimin3 sequence was assembled from GI numbers 51705170 and 28972351 according to human sequence GI: 32469767. (C) Alternative splicing
of zizimin proteins. The zizimin1 and zizimin3 sequences used in (B) are presented schematically and areas of alternative splicing are indicated below.
The length of the alternative splices in amino acids (aa) is indicated. The boundaries of the splicing areas are indicated above the diagrams. (a)
Replacement of the ﬁrst 42 amino acids by MGCTTSVILFKGIRTVFERNCAYMCKQPGESNALEYTAYNWSKEDSELSIAFC according to
Genebank GIs 28972594 and 32469704. (b) Deletion of amino acids 1353–1375 according to GI:28972594. (c) Insertion of EADLALQREPPAF-
PYSHSTCQRKSWG after amino acid 1673 according to GIs 31419757, 34784430 and 28374168. (d) Insertion of AAQYQFTDSETDVE after
amino acid 1788 according to GIs 28972594 and 26337589. (e) Replacement of the carboxy terminus (amino acids 2051-91) by MG according to GIs
28972594 and 26337589. (f) Replacement of the amino terminus by MESRLLWASGNPSASASDQGIPN according to GI 26334085. (g)
Replacement of the carboxy terminus by LCRGPCLYSFCASVSSISLSTVSKSDYGQGRPSKVRSGATLHHTCN according to GI 289723.
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Fig. 2. Zizimin2 binds and activates Cdc42. (A) Schematic representation of the zizimin fragments. Boxes indicate the functional domains as
described. (B) Zizimin2 binds Cdc42. COS-1 cells were transfected with pGT-Zizimin2(669-E) and equal amount of cell lysates were incubated with
nucleotide-depleted Cdc42, Rac1 or RhoA attached to beads. The beads were washed and bound proteins eluted in SDS sample buﬀer, resolved by
SDS–PAGE and detected by Western blotting with anti-HA (upper panel). A portion of the elutes was resolved by SDS–PAGE and stained
by coomassie to detect the GST-Rho proteins (lower panel). Molecular weight standards in kDa are indicated on the left. (C) Cdc42 activation by
zizimin2. pcDNA4-His-max (vector) or full-length (FL) zizimin2 in pcDNA4-His-max (left panel); pGT (GFP), pGT-Zizimin2(1516-E) or pGT-
Zizimin1(1512-E) (right panel), were transfected into COS-1 cells. Activation of endogenous Cdc42 was assayed by precipitating GTP-loaded Cdc42
with bead-bound GST-PAK1-PBD, and detection of Cdc42 in pull downs (upper panels) or total cell lysates (lower panels) by western blotting with
anti-Cdc42. Molecular weight in kDa is indicated on the left.
Fig. 1 (continued)
A. Nishikimi et al. / FEBS Letters 579 (2005) 1039–1046 1043was detected as two protein bands in total lysates, only the
lower band, however, bound Cdc42. For zizimin3, which has
not previously been analyzed, we also tested binding to Rac1
and RhoA. Under the same binding conditions, none of the
GTPases showed consistent binding to zizimin3 CZH2 domain
(data not shown), however, when zizimin3 levels were in-
creased by fourfold, nucleotide-sensitive binding to Cdc42,
TCL and to lesser extent TC10 and Rho was evident. As a po-
sitive control, we used oncoVav1 which was shown to interact
in vitro with Rac, Rho and Cdc42 [26]. OncoVav1 indeed
bound Rac, Rho and Cdc42 as well as TC10 and TCL, demon-
strating activity of the GTPases in this assay (Fig. 3 right pa-nel). Zizimin1 was shown previously to promote ﬁlopodia
formation, indicating that its target GTPase is from the
Cdc42 subfamily [16]. These results strongly support the idea
that Cdc42 is the target for zizimin1 and zizimin2.
3.4. Tissue distribution of zizimin2 and its isoforms
Having cloned zizimin2 by subtractive hybridization as a
gene potentially upregulated in GC B cells, we wished to com-
pare expression of zizimin2 in GC versus non-GC B cells. The
two cell populations were isolated from mouse spleen and zizi-
min2 expression was measured by quantitative RT-PCR. The
results demonstrated that zizimin2 is indeed enriched in GC
Fig. 3. Selectivity of zizimin proteins for Cdc42-related GTPases HA-tagged CZH2 domains of human zizimin proteins (Zizimin11512-E or the
corresponding regions in zizimin2 and ziziminin3) were expressed in COS-7 cells. Cell lysates were incubated with nucleotide-depleted Rho proteins
attached to beads. Bound proteins were eluted in buﬀer containing 5 mMMgCl2 and 100 lMGTPcS. The beads underwent a second elution in SDS
sample buﬀer to release the GST–GTPase fusion proteins. The GTPcS elutes were resolved by SDS–PAGE and zizimin proteins were detected using
Western blotting with anti-HA (left top panel). Total lysates were analyzed in parallel (lysate). The secondary elutes were resolved by SDS–PAGE
and the GST-Rho proteins detected by Coomassie staining (bottom panels). As a positive control, binding of oncoVav1 to the GTPases was assayed
in parallel and detected by Western blotting with anti-myc (top right panel). For zizimin1, zizimin2 and Vav the portions of the total lysate loaded
were 5.3% of the amount used in the pull downs. For zizimin3 fourfold more lysate was used, hence the lysate portion loaded represent 1.3% of the
amount used in the pull down.
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nel). Comparison of zizimin2 expression in splenic mature B
and T lymphocytes revealed a similar expression levels (Fig.
4A right panel).
To gain further insight into the cell-type speciﬁcity of zizi-
min2 expression, we examined murine cell lines from various
origins by quantitative RT-PCR. Zizimin2 mRNA level in
the three B cell lines tested (BAF0/3, WEHI-231 and A20)
was 5–7-fold higher than in NIH-3T3 ﬁbroblasts or Neuro-
2A neuroblastoma cells, while C2C12 myoblasts exhibited an
intermediate level (Fig. 4B). Expression in EL-4 T lymphoma
cells was about twofold lower than in the B cell lines (Fig. 4B).
To examine zizimin2 expression in vivo, we used quantita-
tive RT-PCR to analyze normal mouse tissues and cells.
Expression of zizimin2 was evident in spleen, thymus, bone
marrow and to higher degree in puriﬁed peripheral blood lym-
phocytes (PBL) but was not detected in heart, brain or kidney
(Fig. 4C). Zizimin1 expression showed an opposite pattern,
with high expression in brain and kidney compared to hemato-
poietic tissues and cells (Fig. 4C). To further substantiate these
ﬁndings and to compare expression of the three zizimin iso-
forms in a more rigorous way, we studied mRNA expression
in tissues of 4-week-old mice by Northern blotting (Fig. 4D).
The results conﬁrmed predominant expression of zizimin2 in
hematopoietic organs although low expression level was de-
tected in some of the non-hematopoietic tissues. Zizimin1
was detected most strongly in brain, lung, and kidney as com-
pared to heart, liver, skeletal muscle or hematopoietic organs,
and zizimin3 was enriched in brain, lung, spleen and thymus.
Taken together, these results document predominant expres-
sion of zizimin2 in B and T lymphocytes while zizimin1 is ex-
pressed mainly in non-hematopoietic tissues and cells.
Finally, zizimin2 expression level in normal lymphocytes
versus lymphoma cell lines of diﬀerent diﬀerentiation/diag-
nostic stage was measured by RT-PCR (Fig. 4E). As a gen-
eral rule zizimin2 expression was similar in normal and
transformed cells. Zizimin2 expression was reduced in some
of the lymphomas compared to normal cells, however, this ef-
fect was not consistent and did not correlate with any of themalignancies including acute lymphoblastic leukemia, adult T
cell leukemia, non-Hodgkins lymphoma or multiple
myeloma.4. Discussion
The zizimin subfamily of non-conventional Rho-GEFs in-
cludes three genes named zizimin1/DOCK9, zizimin2/
DOCK11 and zizimin3/DOCK10 [15,16]. We report here the
cloning of zizimin2 in a screen for genes enriched in GC B cells.
Zizimin2 and zizimin1 are similar along their entire length with
60% identity and 75% similarity in amino acid sequence (Fig.
1B). While the target GTPase for both zizimin1 and zizimin2
appear to be Cdc42 (Figs. 2B and 3), the tissue distribution
of the two isoforms is remarkably diﬀerent. Zizimin2 is ex-
pressed predominantly in lymphocytes and zizimin1 is pre-
dominantly expressed in non-hematopoietic tissues and cells
(Fig. 4). This may suggest that zizimin2 was adapted to engage
in lymphocyte-speciﬁc signaling pathways. A similar situation
exists in the DOCK180 subfamily, where DOCK180 is ex-
pressed predominantly in adherent cells and DOCK2 in hema-
topoietic cells [27,28]. Nevertheless, both DOCK180 and
DOCK2 activate Rac proteins and were shown to regulate cell
migration [29,30]. We should note that while in previous study
high expression level of zizimin1 was observed in human heart
and skeletal muscle tissues [16], in this study, done with mouse
tissues, very little or no expression was detected in these tissues
(Fig. 4C and D).
To gain insight into the GTPase speciﬁcity and expression
pattern for the complete zizimin1 subfamily, we also cloned
the CZH2 domain of zizimin3 and studied zizimin3 tissue dis-
tribution. The zizimin3 CZH2 domain interacted with Rho
GTPases as expected, that is, it bound to the nucleotide-free
GTPases and was eluted by GTP. Binding, however, appeared
to be with lower aﬃnity and was more promiscuous (Fig. 3).
The tissue distribution of zizimin3 is distinct from those of zizi-
min1 and zizimin2 and partially overlaps with both (Fig. 4D).
We hypothesize that the target for zizimin3 may be another
Fig. 4. Expression proﬁles of zizimin2 and its isoforms. (A) Expression of zizimin2 mRNA in C57Bl/6J mice splenic lymphocytes. Left panel:
Quantitative real time RT-PCR was carried out on GC B cells (B220+, CD19+, PNAhigh, GL-7+) and non-GC B cells (B220+, CD19+, PNAlow, GL-
7). In each experiment, the increase in zizimin2 mRNA level over the level in non-GC B cells was calculated. Means ± S.D. values of three
experiments are presented. Right panel: Analysis of splenic mature B (B220+) and T cells (CD4+ or CD8+) was done as above, the increase in zizimin2
level over the level in B cells is presented. (B) Expression of zizimin2 mRNA in murine cell lines of diﬀerent origin. Real time RT-PCR analysis was
done as in (A). The bars represent fold increase of zizimin2 mRNA level over the level in NIH-3T3 cells. (C) Expression of zizimin2 and zizimin1
mRNAs in murine tissues. RT-PCR analysis of 4-week-old C57Bl/6J mice tissues was done at the linear range of cycle numbers. The products were
resolved on 2.0% agarose gels and stained by ethidium bromide. (D) Tissue distribution of murine zizimin isoforms. mRNAs from mice tissues as in
(C) was analyzed by Northern blotting. A common membrane was hybridized in succession with 32P-labeled probes from a unique region of each
zizimin isoform or b-actin. RNA molecular size in kb is indicated on the left. (E) Expression of zizimin2 RNAs in human lymphoma cell lines.
Quantitative real time RT-PCR was done as in (A). The bars represent the increase of zizimin2 mRNA level over the level in normal peripheral blood
lymphocytes. The abbreviations below the cell line indicate the diagnosis and lineage of lymphoma. ALL; acute lymphoblastic leukemia, ATL; adult
T cell leukemia, NHL; non-Hodgkins lymphoma, MM; multiple myeloma. (T); T lymphoma and (B); B lymphoma.
A. Nishikimi et al. / FEBS Letters 579 (2005) 1039–1046 1045Rho protein that was not investigated. The cellular signaling
pathways controlled by zizimin proteins are currently un-
known. Future studies will address this intriguing question.
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